Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 2
1981 1
1982 6
1983 4
1985 4
1986 3
1987 5
1988 6
1989 6
1990 5
1991 9
1992 9
1993 13
1994 11
1995 8
1996 17
1997 33
1998 29
1999 31
2000 35
2001 50
2002 57
2003 79
2004 87
2005 126
2006 128
2007 139
2008 178
2009 204
2010 278
2011 287
2012 353
2013 442
2014 498
2015 579
2016 575
2017 699
2018 718
2019 811
2020 1028
2021 1109
2022 658
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

8,343 results
Results by year
Filters applied: . Clear all
Page 1
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients.
Zhang JL, Li YH, Wang LL, Liu HQ, Lu SY, Liu Y, Li K, Liu B, Li SY, Shao FM, Wang K, Sheng N, Li R, Cui JJ, Sun PC, Ma CX, Zhu B, Wang Z, Wan YH, Yu SS, Che Y, Wang CY, Wang C, Zhang Q, Zhao LM, Peng XZ, Cheng Z, Chang JB, Jiang JD. Zhang JL, et al. Among authors: cui jj. Signal Transduct Target Ther. 2021 Dec 6;6(1):414. doi: 10.1038/s41392-021-00835-6. Signal Transduct Target Ther. 2021. PMID: 34873151 Free PMC article.
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, Yu Y, Yao W, Chang J, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Wang J, Li P, Qin M, Lu D, Yang J. Zhou C, et al. Among authors: cui j. Lancet Oncol. 2022 Feb;23(2):220-233. doi: 10.1016/S1470-2045(21)00650-1. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038432 Clinical Trial.
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J, Wu YL. Zhou Q, et al. Among authors: cui j. Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14. Lancet Oncol. 2022. PMID: 35038429 Clinical Trial.
Editorial: Enzyme Biocatalysts: Design and Application.
Cui J, Zheng GW, Black G, Iqbal HMN, Bilal M. Cui J, et al. Front Chem. 2022 Feb 2;10:851857. doi: 10.3389/fchem.2022.851857. eCollection 2022. Front Chem. 2022. PMID: 35186889 Free PMC article. No abstract available.
8,343 results